Log in

Relevant bibliographies by topics / Traumeel® / Journal articles

To see the other types of publications on this topic, follow the link: Traumeel®.

Journal articles on the topic 'Traumeel®'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 15 journal articles for your research on the topic 'Traumeel®.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Birnesser, Heinz, Menachem Oberbaum, Peter Klein, and Michael Weiser. "THE HOMEOPATHIC PREPARATION TRAUMEEL® S COMPARED WITH NSAIDS FOR SYMPTOMATIC TREATMENT OF EPICONDYLITIS." Journal of Musculoskeletal Research 08, no. 02n03 (June 2004): 119–28. http://dx.doi.org/10.1142/s0218957704001284.

Full text

Abstract:

Objective: To compare the homeopathic remedy Traumeel® S with standard NSAID therapy for effects on symptomatic relief in patients with diagnosed epicondylitis. Methods: An observational, non-randomized study over 2 weeks in 184 patients with diagnosed epicondylitis from 38 primary care centers in Germany. At the start of the study, patients were given initial injections of either Traumeel® S or NSAID (unspecified; mainly diclofenac). Traumeel® S patients might have other Traumeel® S injections and other treatments were allowed, e.g. oral analgesics (in the NSAID group only) or physiotherapy. Treatments were evaluated on clinically relevant variables: three pain variables (local pressure pain, pain with movements, pain at rest) and two mobility variables (change in extensional joint mobility and change in torsional joint mobility). Results: Both treatments significantly improved scores on all five variables with no significant differences in time to onset of action. Traumeel® S was equivalent to NSAIDs on all evaluated variables and was significantly superior to NSAID therapy on the variables pain at rest (p<0.01), torsional joint mobility (p<0.01), and extensional joint mobility (p<0.05). Patients' verdicts on the global outcome reflected the results, with the terms "very good" or "good", given by 71.0% of patients in the Traumeel® S group versus 44.2% of patients receiving NSAIDs. Tolerability was good in all groups. Conclusion: Traumeel® S represents an appealing and well-tolerated alternative to NSAIDs for symptomatic treatment of epicondylitis.

APA, Harvard, Vancouver, ISO, and other styles

2

Khaibullina, D. Kh, Yu N. Maksimov, F. I. Devlikamova, and B. Eh Gubeev. "Treatment of cervicogenic headache with application of multicomponent bioregulation drug." Meditsinskiy sovet = Medical Council, no. 8 (July 16, 2020): 95–101. http://dx.doi.org/10.21518/2079-701x-2020-8-95-101.

Full text

Abstract:

Introduction. According to the data of various authors Cervicogenic headache (CH) is met in 2.5 to 70% of population. Diagnostic criteria are described at The International classification of headache (3d revision). CH represents a heterogeneous group of headaches based on functional and organic changes of various anatomical structures of the cervical spine. There are no clinical recommendations for the treatment of patients with CH to date.The purpose of this clinical study is the assessment of the effectiveness of use of Traumeel® S in cervicogenic headache treatment.Materials and methods. 60 patients at the age from 18 to 45, divided into 3 groups were examined. Therapy in various combinations was applied to these patients of all the groups. The 2nd and the 3d groups were treated with the Traumeel® S local injection therapy. The patients of the 4th group were additionally given Traumeel® S in sublingual pill form. The visually analogue scale (VAS), the grading scale of the vertebral neurological symptoms, relapse rate of the CH during a year were applied.Results. The most effective treatment was observed in the 2nd group patients. This was manifested in Better dynamics of pain syndrome and the final result. The CH relapse rate during the year of patients treated with Traumeel® S was significantly lower.Conclusions. Traumeel® S inclusion into combined therapy of CH increases the effectiveness of treatment, helps reduce severity of pain, accelerate the appearance of positive therapeutic effect, operates to reduce severity of vertebral neurological symptoms, reduces frequency of recurrence.

APA, Harvard, Vancouver, ISO, and other styles

3

Ovchinnikov, A. Yu, N. A. Miroshnichenko, Yu O. Nikolaeva, and M. M. Vasilyev. "Several studies on the problem of management patients with chronic tonsillitis during periods of remission and exacerbation." Meditsinskiy sovet = Medical Council, no. 16 (November 14, 2020): 109–15. http://dx.doi.org/10.21518/2079-701x-2020-16-109-115.

Full text

Abstract:

Increase in the number of acute and chronic diseases is a global trend. On the one hand, the emergence of new types of viruses, their active mutation, an increase in antibiotic-resistant bacterial strains, a high frequency of immunodeficiency and allergic diseases contribute to this. On the other hand is inadequate treatment of inflammatory diseases of the upper respiratory tract, widespread use of systemic antibiotics without indications. The use of bioregulatory medicines with proven efficacy in the complex treatment can reduce the drug load on the body, reduce the bacterial complications and side effects. Traumeel®S joins the physiological course of inflammation and activates pro-resolving mediators, contributes to its faster completion and tissue repair. The efficacy and safety of Traumeel®S has been confirmed in many randomized clinical trials. The drug has proven its value in almost any inflammatory pathology of the upper respiratory tract and ear. The drug Lymphomyosot®, a multicomponent agent with lymphatic drainage action, has proven itself perfectly in the complex therapy of chronic tonsillitis. In November 2019, the Council of Experts of the National Medical Association of Otorhinolaryngologists on the problems of pathology of the lympharyngeal ring was held. It is recommended to use the multicomponent bioregulatory preparation Traumeel®S to correct the inflammatory process, which has shown in studies a modulating effect on inflammatory mediators without suppressing COX-2 (prostaglandins). With exacerbation of chronic tonsillitis and lymphadenitis of nonspecific etiology, it is possible to use the multicomponent preparation Lymphomyosot®, which helps to improve the drainage and detoxification function of the lymphatic system.

APA, Harvard, Vancouver, ISO, and other styles

4

Kruglova, L. S., E. V. Ikonnikova, and M. A. Avagumyan. "The effect of post-procedure care on the effectiveness of skin restoration and correction of side effects after aesthetic procedures." Meditsinskiy sovet = Medical Council, no. 12 (September 19, 2021): 340–46. http://dx.doi.org/10.21518/2079-701x-2021-12-340-346.

Full text

Abstract:

Introduction. The duration of the skin healing period and the final result of cosmetic procedures are influenced not only by the treatment protocol and the type of therapy chosen, but also by skin care in the early post-treatment period.Aim of study. Тo study the effectiveness and safety of the use of the topical agent “Traumeel® Cosmo gel” in patients in the early post-treatment period after cosmetic procedures, accompanied by traumatization of the skin.Materials and methods. 20 female patients aged 19 to 49 years, who sought help for the correction of age-related skin changes, acne vulgaris, scarring of the skin and received the procedure of cosmetological therapy, accompanied by damage to the skin. All patients were assigned to group 1 (20 patients). Depending on the method of cosmetological treatment, the external remedy “Traumeel® Cosmo gel” was applied from 2 to 3 times a day at the treated area for 7 ± 2 days.Results. According to the patients’ assessment of the effectiveness and comfort of the treatment, the use of the “Traumeel® Cosmo gel” in the early post-treatment period is an effective and safe method of regenerative therapy of the skin and has a high therapeutic effectiveness, which was confirmed by the results of the study.Conclusions. Based on the results of the evaluation of the effectiveness by the doctor and patients, as well as the evaluation of the monitoring of the dermatological status, the quality of life index, the patient’s subjective assessment of their response to therapy, consider the therapeutic effectiveness to be high, significantly contributing to the improvement of the quality of life.

APA, Harvard, Vancouver, ISO, and other styles

5

Pilipovich, A. A. "he efficacy of Traumeel® S in terms of evidence-based medicine." Consilium Medicum 19, no. 2 (2017): 157–62. http://dx.doi.org/10.26442/2075-1753_19.2.157-162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Maaßen, E., and H. Gerhards. "Equine castration: comparison of treatment with phenylbutazon, Traumeel® and control group." Pferdeheilkunde Equine Medicine 25, no. 5 (2009): 451–60. http://dx.doi.org/10.21836/pem20090502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lussignoli, S., S. Bertani, H. Metelmann, P. Bellavite, and A. Conforti. "Effect of Traumeel S®, a homeopathic formulation, on blood-induced inflammation in rats." Complementary Therapies in Medicine 7, no. 4 (December 1999): 225–30. http://dx.doi.org/10.1016/s0965-2299(99)80006-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ferreira, Patrícia, Mônica Antar Gamba, Humberto Saconato, and Maria Gaby Rivero de Gutiérrez. "Tratamento da mucosite em pacientes submetidos a transplante de medula óssea: uma revisão sistemática." Acta Paulista de Enfermagem 24, no. 4 (2011): 563–70. http://dx.doi.org/10.1590/s0103-21002011000400018.

Full text

Abstract:

OBJETIVO: Identificar as medidas terapêuticas para redução da gravidade da mucosite oral em pacientes adultos submetidos ao Transplante de Medula Óssea (TMO). MÉTODOS: Revisão sistemática nas bases de dados: LILACS, MEDLINE, CINAHL, EMBASE; CENTRAL (Cochrane Central) e DARE (Database of abstracts of reviews of effects), no período de 1972 a julho de 2010, utilizando os descritores mucositis, stomatitis e bone-marrow-transplantation. RESULTADOS: Identificaram-se 3.839 resumos, dos quais 22 foram incluídos na revisão sistemática que descreveram 14 intervenções tópicas e sistêmicas, dentre as quais oito com significância estatística para a redução dessa complicação. As terapias tópicas foram a crioterapia, clorexidine, glutamina, laser e Traumeel® e as sistêmicas, amifostine, Granulokine® e palifermin. CONCLUSÃO: A heterogeneidade dos resultados dessas intervenções e a falta de melhor elucidação para a prática assistencial indicam a necessidade de pesquisas mais precisas para identificar a efetividade de terapias tópicas para a reparação celular das mucosas.

APA, Harvard, Vancouver, ISO, and other styles

9

Wassing, Tina. "Traumeel® ad us. vet.: Wirksame Sofort-Therapie bei akuten Traumata des Bewegungsapparates von Hunden." kleintier konkret 17, no. 04 (September 4, 2014): 42–44. http://dx.doi.org/10.1055/s-0034-1384416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chilla, Almuth. "Anwendungsbeobachtung untersucht Wirksamkeit und Verträglichkeit von Traumeel® ad us. vet. bei Hunden mit akuter unkomplizierter Lahmheit." kleintier konkret 18, no. 03 (June 30, 2015): 51–53. http://dx.doi.org/10.1055/s-0035-1550099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Porozov, Svetlana, Liora Cahalon, Michael Weiser, David Branski, Ofer Lider, and Menachem Oberbaum. "Inhibition of IL-1β and TNF-α Secretion from Resting and Activated Human Immunocytes by the Homeopathic Medication Traumeel® S." Clinical and Developmental Immunology 11, no. 2 (2004): 143–49. http://dx.doi.org/10.1080/10446670410001722203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lozada, C., E. del Rio, D. P. Reitberg, R. Smith, and R. W. Moskowitz. "THU0441 Risk-Benefit of Co-Administered Traumeel® (TR14) and Zeel® (ZE14) Intra-Articular (IA) Injections in Patients with Moderate-to-Severe Pain Associated with OA of the Knee (OAK)." Annals of the Rheumatic Diseases 74, Suppl 2 (June 2015): 359.2–359. http://dx.doi.org/10.1136/annrheumdis-2015-eular.4268.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kovalenko, P. S., I. S. Dydykina, M. V. Zhuravleva, and Ye G. Zotkin. "From Empirical Results of Clinical Efficacy to Evidence of Anti-inflammatory Effects of Traumel® C in vitro and in vivo." Effective Pharmacotherapy 16, no. 6 (March 25, 2020): 16–20. http://dx.doi.org/10.33978/2307-3586-2020-16-6-16-20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ehlert, Dianna, and Ariel Majjhoo. "Traumeel® Epidural Injection: A Viable Alternative to Corticosteroids - A Five-Patient Case Study." Cureus, November 19, 2019. http://dx.doi.org/10.7759/cureus.6196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Singer, Shepherd R., Michal Amit-Kohn, Samuel Weiss, Jonathan Rosenblum, Guy Maoz, Noah Samuels, Esther Lukasiewicz, et al. "Traumeel S® for pain relief following hallux valgus surgery: a randomized controlled trial." BMC Clinical Pharmacology 10, no. 1 (April 12, 2010). http://dx.doi.org/10.1186/1472-6904-10-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!